Table 1 Patient characteristics and clinicopathologic features. (n = 40)
From: Antineoplastic treatment effect on bone mineral density in Mexican breast cancer patients
Premenopausal (n = 19) | Postmenopausal (n = 21) | |
|---|---|---|
Age (mean) | 43 | 53.55 |
Basal BMI (kg/m2, mean) | 28.04 | 31.68 |
Clinical stage | ||
I | 3 | 2 |
IIA | 5 | 7 |
IIB | 3 | 5 |
IIIA | 5 | 4 |
IIIB | 3 | 3 |
Histological subtype | ||
Invasive ductal carcinoma | 18 | 19 |
Invasive lobulillar carcinoma | 1 | 2 |
Treatment | ||
Neoadyuvant | 9 | 9 |
Adyuvant | 10 | 12 |
Molecular subtypes (n = 28)a | ||
Luminal A (RE+, RP+/-, HER2neu-) | 1 | 3 |
Luminal B (RE+, RP+/-, HER2neu+) | 4 | 5 |
HER2 (RE-, RP+/-, HER2+) | 5 | 2 |
Triple negative (RE-, RP-, HER2-) | 5 | 3 |
Chemotherapy schemeb | ||
-FAC (5-Fluorouracile, Adriamicin, Cyclophosphamide) | 15 | 17 |
-FEC (5-Fluorouracile, Epirrubicin, Cyclophosphamide) | - | 1 |
-FAC + P(5-Fluorouracile, Adriamicin, Cyclophosphamide + Paclitaxel) | 3 | 1 |
-FA (5-Fluorouracile, Cyclophosphamide) | 1 | - |
-DAC (Docetaxel, Adriamicin, Cyclophosphamide) | - | 2 |